Freeline Therapeutics Holdings plc
Freeline Therapeutics Holdings plc (FRLN) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
frln · stock forecast · 7 analysts (3M) · FMP · updated Jan 9, 2025
Analyst Rating & Consensus
Based on 7 Wall Street analysts in the past 3 months
Hold
7 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $6.48
Short-Term Price Prediction
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · FRLN · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-11-28 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2023-10-18 | Wedbush | Downgrade ↓ | Outperform→Neutral |
| 2023-10-17 | Wedbush | Downgrade ↓ | Outperform→Neutral |
| 2023-08-17 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-08-16 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-08-16 | Stifel | Maintains | Hold→Hold |
| 2023-08-15 | Stifel | Maintains | Hold→Hold |
| 2023-08-01 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-07-31 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-06-01 | Stifel | Maintains | Hold→Hold |
Wall Street analysts have recently issued updated ratings on Freeline Therapeutics Holdings plc (FRLN) stock. Of the recent 20 rating actions, 1 were upgrades and 6 were downgrades. 7 analysts currently cover FRLN.
Analyst Recommendation Trends
FRLN analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$1M
Revenue Next Year
$1M
↓ 2.8% YoY
EPS This Year
$-12.16
EPS Next Year
$-0.52
↓ 95.7% YoY
EPS ForecastReported vs Estimated
Analysts forecast FRLN EPS of $-12.16 for the current fiscal year, based on estimates from 0 analysts. The FRLN revenue forecast is $1M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The FRLN stock forecast is supported by two independent data sources: analyst consensus ratings from 7 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus FRLN price target is $0.00 (+0.0% upside), with an analyst consensus of Hold.
Freeline Therapeutics Holdings plc trades on NASDAQ under the ticker FRLN. The FRLN stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 29% of covering analysts.
Frequently asked questions
FRLN forecast · 8 questionsAccording to 7 Wall Street analysts, the average 12-month FRLN price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $6.48.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.